

Gavi/14/415/dlc/ac

The Federal Minister of Health Federal Ministry of Health PO Box 303 Khartoum Sudan

23 September 2014

Dear Minister,

Management Letter: Request for 2015 Renewal of Gavi support for renewal of vaccine support

This management letter accompanies the Decision Letter about Sudan's request for renewal for New Vaccines Support (NVS) for Rota, PCV and Pentavalent vaccine which was reviewed by the Gavi Alliance High Level Review Panel (HLRP) on 23-25 July 2014.

The HLRP replaces the monitoring Independent Review Committee in making recommendations to Gavi's Chief Executive Officer on the renewal of Gavi support for existing grants. This change is part of Gavi's new grant application, monitoring and review system, which is designed to lower transaction costs for countries, ensure closer coordination with countries' planning cycles, better align NVS and HSS support, and improve fiduciary oversight. The Review Panel, composed of Alliance partners, is designed to increase the accountability of the Alliance, and to streamline the review processes. The Panel will meet several times a year to enable alignment with countries' budgetary and planning cycles.

This management letter sets out areas on which we would like encourage follow up actions. The Internal Appraisal conducted by Gavi has noted the following recommended areas for action. We encourage you to work to ensure these points are adequately addressed. We request that you review the table below and provide us feedback on the suggested actions and timeframe to address the comments. I would be happy to have a discussion on these comments at your earliest convenience should this be required:

Comment	Suggested Action	Timeframe
To undertake final evaluation of HSS 1 and ensure the findings and recommendations are incorporated through reprogramming in the approved HSS2 grant.		



To take action to finalize and implement the 2014 EVM improvement plan recommendations.		
To ensure robust reporting systems and data quality.		
To ensure more active involvement of CSOs at all levels.		
Allocating budget for traditional routine vaccine procurement and progressively increase same		
The following action points from the financial assessment are recommended to be undertaken in 2014 and 2015 a) update the cMYP reflecting results of the analysis of financial sustainability and consultations with key stakeholders:		
Develop several scenarios based on pessimistic macroeconomic projections	4	
Run consultations with a broad range of stakeholders and partners on the financial sustainability and b) in 2015: Advocate for having a line item in the national budget for traditional vaccines		
ISS: -To provide a detailed breakdown of 2013 ISS expenditure (by economic classification or activity) -Tto submit audit report for 2013		
HSS: -To submit audit report for 2013 -To provide copy of the bank statement showing receipt of HSS funds transferred by Gavi in 2013 -To provide 2013 financial statement, clearly showing opening balance, funds received, detailed expenditure (for example by activity) and closing balance,		



in US \$, local currency and EUR	
NVS -To provide a detailed breakdown of 2013 NVS expenditure (by economic classification or activity) -To submit audit report for 2013	
cos -Separate 2012 and 2013 financial statements to be provided by UNICEF and WHO relating to Campaign Operational Support (COS) Funds	

The Decision Letter and related appendices are attached to this message. Please do not hesitate to contact me at acronin@gavi.org if you have any questions or concerns. I would be happy to set up a teleconference to discuss this further should this be required.

Yours sincerely,

Anne Cronin

Senior Country Manager

ane Comen

Attachments: Sudan's Internal Appraisal

cc: The Minister of Finance

The Director of Medical Services Director Planning Unit, MoH

The EPI Manager

WHO Country Representative UNICEF Country Representative

Regional Working Group

WHO HQ

UNICEF Programme Division

The World Bank



Annexe B-1

Republic of Sudan VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1.	Country: Sudan	, Republic of			
2.	Grant Number:	1516-SDN-04a-X			
3.	Date of Decision	Letter: 23/09/2014			
4.	Date of the Part	nership Framework	Agreement: 10/1	2/2013	
5.	Programme Titl	e: NVS, Pentavalen	t Routine		
6.	Vaccine type: Po	entavalent			
7.	Requested prod per vial, LIQUI	uct presentation and D	d formulation of v	accine: DTP-Hep	B-Hib, 1 dose(s)
8.	Programme Dui	ration ¹ : 2008 - 2016			
9.	Programme Bud Agreement):	lget (indicative) (sul	bject to the terms	of the Partnership	Framework
		2008-2014	2015	2016	Total ²
Progra (US\$)	amme Budget	US\$75,907,448 ³	US\$7,444,500	US\$9,641,500	US\$92,993,448
10	. Vaccine Introdu	ection Grant: Not ap	pplicable		

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.



11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴

Type of supplies to be purchased with Gavi funds in each year	2008-2014	2015
Number of Pentavalent vaccines doses		3,598,400
Number of AD syringes		3,844,000
Number of re-constitution syringes		
Number of safety boxes		42,300
Annual Amounts (US\$)	US\$75,907,448 ⁵	US\$7,444,500

- **12. Procurement agency:** UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.
- 13. Self-procurement: Not applicable.
- **14.** Co-financing obligations: Reference code: 1516-SDN-04a-X-C. According to the Co-Financing Policy, the Country falls within the group Intermediate.

 The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each	2015	2016
year		
Number of vaccine doses	610,400	1,021,300
Number of AD syringes	652,000	
Number of re-constitution syringes		
Number of safety boxes	7,175	
Value of vaccine doses (US\$)	US\$1,189,581	
Total Co-Financing Payments (US\$) (including freight)	US\$1,263,000	US\$2,044,000

15. Operational support for campaigns: Not applicable

This is the amount that GAVI has approved.

This is the consolidated amount for all previously approved years.



Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with Gavi Secretariat in the context of GAMR Joint Appraisal process on support for the year 2014
17. Financial Clarifications: The Country shall p *Failure to provide the financial clarifications reque disbursements	

Signed by,

On behalf of the Gavi Alliance

Hind Khatib-Othman Managing Director, Country Programmes 23 September 2014

What Ho brist



Annexe B-2

Republic of Sudan VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Co	ıntry: Sudan, Republi	c of			
2. Gr	ant Number: 1516-SD	N-13b-X			
3. Da	e of Decision Letter: 2	3/09/2014			
4. Da	e of the Partnership F	ramework Agreen	nent: 10/12/2013		
5. Pro	gramme Title: NVS, F	Rotavirus Routine			
6. Va	ccine type: Rotavirus				
	quested product preser edule	ntation and formu	ation of vaccine: I	Rotavirus, 2 dose(s)	
8. Pro	gramme Duration ⁶ : 20	011 - 2016			
	gramme Budget (indicreement):	cative) (subject to	the terms of the Pa	artnership Framewo	ork
	2011-2014	2015	2016	Total ⁷]
Programme Budget (US\$)	US\$22,444,754 ⁸	US\$4,418,000	US\$6,675,000	US\$33,537,754	
10. Va	ccine Introduction Gra	ant: Not applicable			

 $^{^6}$ This is the entire duration of the programme. 7 This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

⁸ This is the consolidated amount for all previous years.



11.	Indicative Annual	Amounts (subject to	the terms of the	Partnership	Framework
	Agreement):9				

Type of supplies to be purchased with Gavi funds in each year	2011-2014	2015
Number of Rotavirus vaccines doses		1,665,000
Number of AD syringes		
Number of re-constitution syringes		
Number of safety boxes		
Annual Amounts (US\$)	US\$22,444,754	US\$4,418,000

- **12. Procurement agency:** UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.
- 13. Self-procurement: Not applicable.
- **14.** Co-financing obligations: Reference code: 1516-SDN-13b-X-C. According to the Co-Financing Policy, the Country falls within the group Intermediate.

 The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015	2016
Number of vaccine doses	213,000	372,000
Number of AD syringes		
Number of re-constitution syringes		
Number of safety boxes		
Value of vaccine doses (US\$)	US\$542,160	
Total Co-Financing Payments (US\$) (including freight)	US\$563,500	US\$999,500

15. Operational support for campaigns: Not applicable

⁹ This is the amount that GAVI has approved.



To be agreed with Gavi Secretariat in the context of GAMR Joint Appraisal process on support for the
year 2014
e following clarifications to Gavi*: result in Gavi withholding further

Signed by,

On behalf of the Gavi Alliance

Hind Khatib-Othman Managing Director, Country Programmes 23 September 2014

Blind A. Thalib



Annexe B-3

Republic of Sudan VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

_											
	1. Country: Sudan, Republic of										
	2. (2. Grant Number: 1516-SDN-12c-X									
	3. [3. Date of Decision Letter: 23/09/2014									
	4. Date of the Partnership Framework Agreement: 10/12/2013										
	5. Programme Title: NVS, Pneumococcal Routine										
	6. Vaccine type: Pneumococcal										
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID											
	8. Programme Duration ¹⁰ : 2013 - 2016										
	9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):										
			2013-2014	2015	2016	Total ¹¹					
	Program Budget (US\$)	ime	US\$39,227,000 ¹²	US\$22,357,500	US\$18,606,000	US\$80,190,500					
-	10. Vaccine Introduction Grant: Not applicable										

This is the entire duration of the programme.

This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

This is the consolidated amount for all previous years.



11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):13

Type of supplies to be purchased with Gavi funds in each year	2013-2014	2015
Number of Pneumococcal vaccines doses		4,057,200
Number of AD syringes		4,251,400
Number of re-constitution syringes		
Number of safety boxes		46,775
Annual Amounts (US\$)	US\$39,227,000 ¹⁴	US\$22,357,500

- 12. Procurement agency: UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.
- 13. Self-procurement: Not applicable.
- 14. Co-financing obligations: Reference code: 1516-SDN-12c-X-C. According to the Co-Financing Policy, the Country falls within the group Intermediate. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each	2015	2016
year		
Number of vaccine doses	315,000	374,400
Number of AD syringes	328,200	
Number of re-constitution syringes		
Number of safety boxes	3,625	
Value of vaccine doses (US\$)	US\$1,055,790	
Total Co-Financing Payments (US\$) (including freight)	US\$1,137,000	US\$1,349,000

15. Operational support for campaigns: Not applicable

 $^{^{13}}$ This is the amount that GAVI has approved. 14 This is the consolidated amount for all previously approved years.



16. Additional documents to be delivered for future disbursements: Not applicable					
Reports, documents and other deliverables	Due dates				
Annual Progress Report or equivalent	To be agreed with Gavi Secretariat in the context of GAMR Joint Appraisal process on support for the year 2014				
17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*:					
*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements					
18. Other conditions: Not applicable.					

Signed by,

On behalf of the Gavi Alliance

Hind Khatib-Othman Managing Director, Country Programmes 23 September 2014

Hital H. Thatel.